CoChat

A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia

Open access
Vu, Khanh, Busaidy, Naifa, Cabanillas, Maria E., Konopleva, Marina, Faderl, Stefan, Thomas, Deborah A., O'Brien, Susan, Broglio, Kristine, Ensor, Joe, Escalante, Carmen, Andreeff, Michael, Kantarjian, Hagop, Lavis, Victor, Yeung, Sai-Ching Jim · 2012 · Clinical Lymphoma Myeloma and Leukemia
Cited by 44

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

INTRODUCTION Hyperglycemia during hyper-CVAD chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL). PATIENTS/METHODS To examine whether an intensive insulin regimen could improve outcomes compared with conventional anti-diabetic pharmacotherapy, a randomized trial was conducted comparing glargine plus aspart versus conventional therapy (control). Between 4/2004 and 7/2008, 52 newly diagnosed ALL, Burkitt’s lymphoma, or lymphoblastic lymphoma patients on hyper-CVAD in the inpatient setting and had random serum glucose >180 mg/dL in ≥ 2 occasions during chemotherapy were enrolled. RESULTS The trial was terminated early due to futility regarding ALL clinical outcomes despite improved glycemic control. Secondary analysis revealed that molar insulin-to-C-peptide ratio (I/C) >0.175 (a surrogate measure of exogenous insulin usage) was associated with decreased overall survival, complete remission duration and progression-free survival (PFS) while metformin and/or thiazolidinedione usage were associated with increased PFS. In multivariate analyses, factors which significantly predicted short overall survival included age≥60 years (P=0.0002), I/C≥0.175 (P=0.0016) and average glucose≥180 mg/dL (P=0.0236). Factors that significantly predicted short progression-free survival included age≥60 years (P=0.0008), I/C≥0.175 (P=0.0002), high systemic risk (P=0.0173) and average glucose≥180 mg/dL (P=0.0249). I/C ≥ 0.175 was the only significant (P=0.0042) factor that predicted short complete remission duration. CONCLUSION A glargine-plus-aspart intensive insulin regimen did not improve ALL outcomes in hyperglycemic patients. Exogenous insulin may be associated with poor outcomes while metformin and thiazolidinediones may be associated with improved outcomes. These results suggest that the choice of anti-diabetic pharmacotherapy may influence ALL outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.clml.2012.05.004

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

Metadata

Authors
Vu, K., Busaidy, N., Cabanillas, M. E., Konopleva, M., Faderl, S., Thomas, D. A., O'Brien, S., Broglio, K., Ensor, J., Escalante, C., Andreeff, M., Kantarjian, H., Lavis, V., & Yeung, S.-C. J.
Venue
Clinical Lymphoma Myeloma and Leukemia
Publisher
Elsevier BV
Published
2012-10
Volume
12
Issue
5
Pages
355-362
ISSN
2152-2650 (ISSN-L)
OpenAlex
W2084139498
Cited by
44
References
4
FWCI
4.05
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.